What is the revenue and EPS growth rate for Definium year over year?

What were the key takeaways from Definium’s earnings call?

What is Definium's latest dividend and current dividend yield?

What guidance did Definium's management provide for the next earnings period?

What does Definium do and what are its main business segments?

What is Definium's gross profit margin?

Did Definium beat or miss consensus estimates last quarter?

What were the key takeaways from Definium's earnings call?

- **Pivotal Year Ahead**: 3 Phase 3 readouts in 2026 (MDD: Q2, GAD: Q3) with DT120 showing 99%+ statistical power in GAD interim analysis.
- **Strong Financial Backing**: $411.6M cash runway into 2028 with focus on NDA preparation and commercial infrastructure.
- **Best-in-Class Potential**: DT120 demonstrates 7.7/6.4-point HAM-A/MADRS improvements vs <4-point for current therapies.
- **Commercial Readiness**: High-touch provider model with centralized hub services to streamline access and reimbursement.

**【Management Opening Remarks】**
- CEO Rob Barrow highlighted Definium’s momentum with 3 pivotal Phase 3 readouts expected in 2026: Emerge (MDD) in Q2, Voyage (GAD) in Q3, and Ascend (MDD) later in the year.
- Emphasized DT120 ODT’s potential as a best-in-class psychedelic therapy with strong clinical data showing 7.7-point HAM-A and 6.4-point MADRS improvements in Phase 2b.
- Announced refreshed brand positioning and commercial readiness for potential 2026 launches in GAD and MDD.

**【CEO Commentary】**
- **MDD Program Progress**: Emerge (100mcg vs placebo) fully enrolled with Q2 readout; Ascend (100mcg/50mcg vs placebo) activating sites for Q2 dosing.
- **GAD Program Update**: Voyage (100mcg vs placebo) 80% enrolled with interim analysis showing 99%+ power to detect 5-point HAM-A difference; Panorama (100mcg/50mcg vs placebo) progressing on track for H2 readout.
- **Interim Analysis Insights**: Voyage’s blinded sample size re-estimation showed 6.7-point observed HAM-A SD vs 10-point assumption, reducing required separation to <2 points for significance.

**【CFO Commentary】**
- **2025 Financials**: R&D expenses $117.7M (vs $65.3M in 2024), G&A $48.6M (vs $38.6M), net loss $183.8M driven by warrant valuation changes.
- **Cash Position**: $411.6M as of Dec 31, 2025, supporting operations into 2028.
- **2026 Focus**: Accelerating NDA preparation, market access, and KOL education.

**【Q&A Highlights】**
- **Clinical Confidence**: Interim data shows DT120’s statistical power >99% in GAD; durability data from Part B extensions to be shared post-readout.
- **Commercial Strategy**: High-touch provider support model with centralized hub services for reimbursement and logistics.
- **Regulatory Pathway**: Potential for single pivotal study filing if data supports, but plans to pursue dual indication submissions.
- **ASD Program Update**: DT-402 Phase 2a study dosing first participants, targeting core ASD symptoms with functional biomarkers.


Definium Therapeutics Inc (DFTX) Q4 2025 Earnings Call Transcript

- **$259M Fundraise Strengthens Pipeline**: Accelerates MM120 NDA prep and MM402 development.
- **2026 Pivotal Readouts**: Three phase 3 studies deliver GAD and MDD data, with Emerge advancing to mid-2026.
- **ASD Breakthrough Potential**: MM402 phase 2A to test chronic administration for social communication in ASD.
- **Financial Resilience**: $242.8M net proceeds extend cash runway to 2028, supporting aggressive execution.

**【CEO Summary Section】**
- Secured $259M gross proceeds from a public offering, enhancing cash runway into 2028.
- Phase 3 studies for MM120 (GAD and MDD) on track for 2026 readouts: Voyage (Q2 2026), Panorama (Q4 2026), and Emerge (mid-2026 due to faster enrollment).
- Initiated MM402 phase 2A study for ASD, targeting 20 participants in Q4 2025.
- Expanded investor base with healthcare-dedicated funds, strengthening long-term shareholder support.

**【CMO Clinical Update】**
- Phase 3 GAD studies (Voyage, Panorama) powered to detect 5-point HamA improvement vs. placebo, using 100μg MM120 ODT.
- Phase 2B results published in JAMA: 7.7-point placebo-adjusted reduction in HamA at week 12, 65% response rate, 48% remission.
- Addressed functional unblinding with blinded raters, expectancy bias questionnaires, and control arms with perceivable effects.
- MM402 phase 1 data supports tolerability; phase 2A to assess efficacy in ASD social communication challenges.

**【CFO Financial Commentary】**
- Q3 2025 cash balance: $209.1M; post-offering net proceeds: $242.8M.
- R&D expenses: $31M (vs. $17.2M in Q3 2024), driven by MM120 and MM402 programs.
- G&A expenses: $14.7M (vs. $7.6M), reflecting commercial readiness and expanded capabilities.
- Net loss: $67.3M, impacted by $22.5M warrant fair value change.

**【Q&A Highlights】**
- Emerge study accelerated to mid-2026 readout due to faster enrollment; no plans to upsize trials.
- MM402 designed for daily or as-needed use, targeting ASD social communication deficits.
- FDA alignment on phase 3 designs; no advisory committee required yet.
- KOLs enthusiastic about MM120's potential, driven by durability and monotherapy efficacy.
- Commercial strategy focuses on NDA preparation, reimbursement pathways, and provider education.

Mind Medicine Inc (MNMD) Q3 2025 Earnings Call Transcript

- **Clinical Momentum**: Phase III trials for MM120 ODT in GAD and MDD on track with strong enrollment, targeting 2026 top-line readouts.
- **Financial Strength**: $237.9M cash runway supports operations into 2027, with R&D expenses ramping up for pivotal trials.
- **Commercial Focus**: Building infrastructure for launch, targeting high-volume psychiatric sites and developing reimbursement strategies.
- **Strategic Leadership**: New CFO Brandi Roberts brings proven track record of scaling operations and executing strategic financings.
- **Differentiated Product**: MM120's 48% remission rate and durable effects (12+ weeks in Phase II) position it as best-in-class psychedelic therapy.

**【CEO Summary Section】**
- **Phase III Trials Progressing Strongly**: MM120 ODT Phase III trials for GAD (Voyage, Panorama) and MDD (Emerge) are on track with strong enrollment trends. Top-line data expected in 2026.
- **Breakthrough Therapy Designation**: FDA granted Breakthrough Therapy Designation for MM120 ODT in GAD, driven by Phase IIb results showing 48% remission rate at week 12.
- **Commercial Readiness**: Building team and infrastructure for launch, with 78% of interventional psychiatrists看好 psychedelic therapies for GAD/MDD.
- **New CFO Appointment**: Brandi Roberts (25+ years life sciences experience) joins to lead financial strategy, including IPO and $2.6B acquisition at Longboard Pharmaceuticals.

**【CFO Financial Commentary】**
- **Cash Position**: $237.9M as of Q2 2025, sufficient for operations into 2027 and 12 months post first Phase III readout.
- **R&D Expenses**: $29.8M (Q2 2025) vs $14.6M (Q2 2024), driven by Phase III trial costs (+$14.5M) and headcount growth (+$1.5M).
- **G&A Expenses**: $11.1M (Q2 2025) vs $9.8M (Q2 2024), due to commercialization preparation and headcount expansion.
- **Financial Strategy**: Maintaining flexibility with amended K2 debt agreement, focusing on capital efficiency and shareholder value.

**【Q&A Key Highlights】**
- **Enrollment & Adaptive Design**: Trials using adaptive design to maintain statistical power, with potential 50% enrollment increase if needed. Phase IIb showed 8-point HAM-A improvement vs placebo.
- **Commercial Strategy**: Focusing on practice economics, targeting high-volume GAD/MDD sites, and building reimbursement pathways. Open-label extension phase designed to mimic real-world treatment patterns.
- **FDA Interaction**: Productive engagement with FDA, with Phase III designs aligned with regulatory guidance. Breakthrough Therapy Designation supports potential accelerated pathway.
- **IP Strategy**: Confident in IP portfolio, with granted patents and ongoing filings to protect innovations in psychedelic therapy delivery.
- **Market Differentiation**: MM120's single-dose durability (12+ weeks in Phase II) and 48% remission rate differentiate it from competitors.


Mind Medicine (MNMD)-31 Jul 25-2025 Q2 Earnings call transcript

- **Clinical Momentum:** Three Phase III trials for MM-120 ODT in GAD and MDD actively enrolling, with data expected in 2026.
- **Financial Strength:** $245.5M cash runway into 2027; R&D ramping up for pivotal trials.
- **Key Dose Decision:** 100μg MM-120 ODT selected for Phase III based on Phase IIb results; 50μg dose for blinding only.
- **Market Opportunity:** ~50M U.S. GAD patients; strong commercial potential if approved.
- **FDA Support:** Breakthrough Therapy Designation for GAD; no regulatory delays anticipated.


**【CEO Opening Remarks】**
- Highlighted May as Mental Health Awareness Month, emphasizing the company's mission to address unmet needs in GAD and MDD.
- Announced three pivotal Phase III trials (Voyage, Panorama, Emerge) for MM-120 ODT, with enrollment progressing strongly.
- Expected top-line data from Voyage (GAD) in H1 2026, Panorama (GAD) in H2 2026, and Emerge (MDD) in H2 2026.
- Breakthrough Therapy Designation for MM-120 ODT in GAD, targeting ~50M U.S. patients.

**【CFO Financial Update】**
- Q1 2025 cash balance: $245.5M, sufficient for operations into 2027.
- R&D expenses: $23.4M (vs. $11.7M YoY), driven by Phase III trials.
- G&A expenses: $8.8M (vs. $10.5M YoY), down due to reduced stock-based compensation.
- Amended $120M loan facility with K2 HealthVentures for financial flexibility.

**【CMO Clinical Program Update】**
- **GAD Trials (Voyage/Panorama):** 12-week efficacy phase and 40-week extension for durability.
  - Primary endpoint: HAM-A score change vs. placebo.
  - Adaptive design allows up to 50% enrollment increase if needed.
- **MDD Trial (Emerge):** Single-dose MM-120 vs. placebo, with MADRS score as primary endpoint.
  - Open-label extension for long-term safety and efficacy.
- No interim data releases planned before 2026 readouts.

**【Q&A Highlights】**
- **Dose Selection:** 100μg MM-120 ODT chosen based on Phase IIb efficacy; 50μg dose in GAD trials is for blinding, not efficacy assessment.
- **FDA Engagement:** Strong dialogue with agency; no impact from leadership changes observed.
- **Commercial Strategy:** Leveraging Spravato's infrastructure but targeting distinct GAD/MDD patient pools.
- **Safety Monitoring:** CSSRS assessments for suicidality; no safety signals in Phase II.
- **Pipeline Update:** MM-402 Phase I completed; next steps TBD.


Mind Medicine (MNMD)-8 May 25-2025 Q1 Earnings call transcript

- **Clinical Momentum**: Dosed patients in all 3 Phase III trials; GAD trials on track for 2026 readouts.
- **Breakthrough Designation**: FDA granted Breakthrough Therapy Designation for MM120 in GAD.
- **Financial Security**: $273.7M cash runway supports operations into 2027.
- **Market Opportunity**: Addresses 51M U.S. adults with GAD/MDD; Phase IIb showed 8-point HAM-A improvement vs placebo.
- **Operational Efficiency**: Adaptive trial design allows up to 50% enrollment increase without statistical penalty.


**【CEO Opening Remarks】**
- **2024 Milestones**: Achieved key milestones for MM120 Phase III program, including positive Phase IIb results in GAD and FDA Breakthrough Therapy Designation.
- **Clinical Progress**: Dosed patients in both GAD Phase III trials (Voyage and Panorama) with strong enrollment trends. First MDD trial (Emerge) expected to dose in H1 2025.
- **Financial Strength**: $273.7M cash runway as of Q4 2024, sufficient for operations into 2027 and 12+ months post first Phase III readout.

**【CMO Clinical Update】**
- **GAD Trials**: 
  - **Voyage**: 200 participants, 1:1 MM120 100mcg vs placebo; primary endpoint: 12-week HAM-A change.
  - **Panorama**: 250 participants, 2:1:2 MM120 100mcg/50mcg vs placebo; adaptive design with 50% potential enrollment increase.
- **MDD Trial (Emerge)**: 140 participants, 1:1 MM120 100mcg vs placebo; primary endpoint: 6-week MADRS change.
- **Design Features**: Central raters, adaptive sample size re-estimation, and exclusion of recent psychedelic use.

**【Financial Highlights】**
- **Cash Position**: $273.7M as of Dec 31, 2024 (vs $99.7M in 2023).
- **R&D Expenses**: $65.3M for 2024 (+$13.2M YoY) driven by Phase III trials and MM402 program.
- **G&A Expenses**: $38.6M for 2024 (-$3.1M YoY) due to reduced professional fees.
- **Net Loss**: $108.6M for 2024 (+$12.9M YoY) driven by R&D investments.

**【Q&A Key Takeaways】**
- **Enrollment Trends**: Encouraging early participation in GAD trials, mirroring Phase IIb demographics.
- **Adaptive Design**: No alpha spend; re-estimation based on dropout rate (15%) and HAM-A variance.
- **Market Potential**: MM120 targeting 51M U.S. adults with GAD/MDD; Phase III data expected H2 2026.
- **Competitive Edge**: Single-dose durability and reduced site logistics complexity vs. daily therapies.


Actual	-1.35	-0.9	-0.6	-0.6	-0.6	-0.56	-0.13	-0.65	-0.76	-0.45	-0.58	-1.14	-0.08	-0.18	-0.41	-0.27	-0.5	-0.78	-0.51
Forecast	-0.6	-0.525	-0.675	-0.75	-0.75	-0.5946	-0.4917	-0.4217	-0.5336	-0.6543	-0.4629	-0.5286	-0.327	-0.277	-0.293	-0.363	-0.38	-0.5013	-0.4837
Surprise	-125.00%	-71.43%	+11.11%	+20.00%	+20.00%	+5.82%	+73.56%	-54.14%	-42.43%	+31.22%	-25.30%	-115.66%	+75.54%	+35.02%	-39.93%	+25.62%	-31.58%	-55.60%	-5.44%

Actual	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Forecast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

DFTX

DFTX fundamentals

DFTX Q4 2025 Earnings

Earnings Call

You can ask Aime

DFTX

DFTX fundamentals

DFTX Q4 2025 Earnings

Earnings Call

DFTX Earnings Call Summary for Q4/20254:30 PM on Feb 26, 2026

DFTX Earnings Call Summary for Q3/20254:30 PM on Nov 6, 2025

DFTX Earnings Call Summary for Q2/20254:30 PM on Jul 31, 2025

DFTX Earnings Call Summary for Q1/20258:00 AM on May 8, 2025

DFTX Earnings Call Summary for Q4/20248:00 AM on Mar 6, 2025

You can ask Aime